



आयुर्वेद शिक्षण एवं अनुसंधान संस्थान

Institute of Teaching and Research in Ayurveda

राष्ट्रीय महत्व का संस्थान, आयुष मंत्रालय, भारत सरकार

Institute of National Importance, Ministry of Ayush, Government of India

Website: <https://itra.ac.in> Email: ethics@itra.edu.in

Serious Adverse Event Reporting Format (Clinical Trials)

1. Title of the study.....

.....

2. Principal Investigator (Name, Designation and Affiliation).....

.....

3. Participant details:

Initials and Case No./Subject ID

Age at the time of event.....

Gender - Male/ Female

Weight: (Kg.)

Height:(cm.)

4. Report type: Initial Follow-up Final

If Follow-up report, state date of Initial report

What was the assessment of relatedness to the trial in the initial report?

By PI- Related

By sponsor - Related

By EC - Related

Unrelated

Unrelated

Unrelated

5. Describe the event and specify suspected SAE diagnosis.....

6. Date of onset of SAE..... Date of reporting.....

7. Onset lag time after administration of intervention.....

Location of SAE (Clinic/Ward/Home/Other)

8. Details of suspected study drug/device/investigational procedure causing SAE:

I. Suspect study drug (include generic name) device/intervention

.....

II. Indication(s) for which suspect study drug was prescribed or tested

.....

III. Route(s) of administration, daily dose and regimen, dosage form and strength

IV. Therapy start date Stop date.....

9. Was study intervention discontinued due to event? Yes/ No

10. Did the reaction decline after stopping or reducing the dosage of the study drug / procedure? Yes/No

If yes, provide details about the reduced dose.....

11. Did the reaction reappear after reintroducing the study drug / procedure? Yes/No/ NA

If yes, provide details about the dose.....

12. Concomitant study drugs history and lab investigations:

I. Concomitant study drug (s) and date of administration.....

.....

II. Relevant test/laboratory data with dates.....

.....

.....

III. Patient relevant history including pre-existing medical conditions (e.g. allergies, race, pregnancy, smoking, alcohol use, hepatic/ renal dysfunction etc)

.....

13. Have any similar SAE occurred previously in this study? Yes/No

If yes, please provide details.....

14. Seriousness of the SAE:

- Death
- Life threatening
- Hospitalization-initial or prolonged
- Disability
- Congenital anomaly
- Required intervention to prevent permanent impairment / damage
- Others (specify)

15. Describe the medical management provided for adverse reaction (if any) to the research participant. (Include information on who paid, how much was paid and to whom).....

.....

16. Outcome of SAE:

- Fatal
- Continuing
- Recovering
- Recovered

- Unknown
- Other (specify)

17. Was the research subject continued on the trial? Yes/ No /NA

18. Provide the details about PI final assessment of SAE relatedness to trial.....
.....

19. Has this information been communicated to sponsor/CRO/regulatory agencies? Yes/ No
Provide details if communicated (including date).....

20. Does this report require any alteration in trial protocol? Yes/No

21. Provide details of compensation provided/ to be provided the participants (include information on who pays, how much, and to whom)

.....

Signature of PI

Date: